Literature DB >> 26033126

Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies.

Carolyn S Calfee1, David R Janz2, Gordon R Bernard2, Addison K May2, Kirsten N Kangelaris3, Michael A Matthay4, Lorraine B Ware2.   

Abstract

BACKGROUND: ARDS is a heterogeneous syndrome that encompasses lung injury from both direct and indirect sources. Direct ARDS (pneumonia, aspiration) has been hypothesized to cause more severe lung epithelial injury than indirect ARDS (eg, nonpulmonary sepsis); however, this hypothesis has not been well studied in humans.
METHODS: We measured plasma biomarkers of lung epithelial and endothelial injury and inflammation in a single-center study of 100 patients with ARDS and severe sepsis and in a secondary analysis of 853 patients with ARDS drawn from a multicenter randomized controlled trial. Biomarker levels in patients with direct vs indirect ARDS were compared in both cohorts.
RESULTS: In both studies, patients with direct ARDS had significantly higher levels of a biomarker of lung epithelial injury (surfactant protein D) and significantly lower levels of a biomarker of endothelial injury (angiopoietin-2) than those with indirect ARDS. These associations were robust to adjustment for severity of illness and ARDS severity. In the multicenter study, patients with direct ARDS also had lower levels of von Willebrand factor antigen and IL-6 and IL-8, markers of endothelial injury and inflammation, respectively. The prognostic value of the biomarkers was similar in direct and indirect ARDS.
CONCLUSIONS: Direct lung injury in humans is characterized by a molecular phenotype consistent with more severe lung epithelial injury and less severe endothelial injury. The opposite pattern was identified in indirect lung injury. Clinical trials of novel therapies targeted specifically at the lung epithelium or endothelium may benefit from preferentially enrolling patients with direct and indirect ARDS, respectively.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26033126      PMCID: PMC4451708          DOI: 10.1378/chest.14-2454

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  36 in total

Review 1.  Pulmonary and extrapulmonary acute respiratory distress syndrome are different.

Authors:  P Pelosi; D D'Onofrio; D Chiumello; S Paolo; G Chiara; V L Capelozzi; C S V Barbas; M Chiaranda; L Gattinoni
Journal:  Eur Respir J Suppl       Date:  2003-08

Review 2.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

3.  The circulating glycosaminoglycan signature of respiratory failure in critically ill adults.

Authors:  Eric P Schmidt; Guoyun Li; Lingyun Li; Li Fu; Yimu Yang; Katherine H Overdier; Ivor S Douglas; Robert J Linhardt
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

4.  Clinical and epidemiologic phenotypes of childhood asthma.

Authors:  Martin Depner; Oliver Fuchs; Jon Genuneit; Anne M Karvonen; Anne Hyvärinen; Vincent Kaulek; Caroline Roduit; Juliane Weber; Bianca Schaub; Roger Lauener; Michael Kabesch; Petra Ina Pfefferle; Urs Frey; Juha Pekkanen; Jean-Charles Dalphin; Josef Riedler; Charlotte Braun-Fahrländer; Erika von Mutius; Markus J Ege
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

5.  Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury.

Authors:  Lorraine B Ware; Mark D Eisner; B Taylor Thompson; Polly E Parsons; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2004-06-16       Impact factor: 21.405

6.  Protein C and thrombomodulin in human acute lung injury.

Authors:  Lorraine B Ware; Xiaohui Fang; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-05-16       Impact factor: 5.464

7.  Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome.

Authors:  Akitoshi Ishizaka; Tomoyuki Matsuda; Kurt H Albertine; Hidefumi Koh; Sadatomo Tasaka; Naoki Hasegawa; Nobuoki Kohno; Toru Kotani; Hiroshi Morisaki; Junzo Takeda; Morio Nakamura; Xiaohui Fang; Thomas R Martin; Michael A Matthay; Satoru Hashimoto
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-09-05       Impact factor: 5.464

8.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

9.  Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury.

Authors:  M D Eisner; P Parsons; M A Matthay; L Ware; K Greene
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

10.  Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome.

Authors:  Lorraine B Ware; Tatsuki Koyama; Zhiguo Zhao; David R Janz; Nancy Wickersham; Gordon R Bernard; Addison K May; Carolyn S Calfee; Michael A Matthay
Journal:  Crit Care       Date:  2013-10-24       Impact factor: 9.097

View more
  148 in total

1.  Alveolar heparan sulfate shedding impedes recovery from bleomycin-induced lung injury.

Authors:  W B LaRivière; S Liao; S A McMurtry; K Oshima; X Han; F Zhang; S Yan; S M Haeger; M Ransom; J A Bastarache; R J Linhardt; E P Schmidt; Y Yang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-04-22       Impact factor: 5.464

Review 2.  Phenotypes in acute respiratory distress syndrome: moving towards precision medicine.

Authors:  Pratik Sinha; Carolyn S Calfee
Journal:  Curr Opin Crit Care       Date:  2019-02       Impact factor: 3.687

3.  Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome.

Authors:  Nadir Yehya; Neal J Thomas; Nuala J Meyer; Jason D Christie; Robert A Berg; Susan S Margulies
Journal:  Intensive Care Med       Date:  2016-04-21       Impact factor: 17.440

4.  Biomarkers of ARDS: what's new?

Authors:  Lorraine B Ware; Carolyn S Calfee
Journal:  Intensive Care Med       Date:  2015-07-15       Impact factor: 17.440

Review 5.  Fifty Years of Research in ARDS. Genomic Contributions and Opportunities.

Authors:  John P Reilly; Jason D Christie; Nuala J Meyer
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

Review 6.  The Angiopoietin-Tie2 Signaling Axis in Systemic Inflammation.

Authors:  Samir M Parikh
Journal:  J Am Soc Nephrol       Date:  2017-05-02       Impact factor: 10.121

7.  Time to evaluate biomarkers for use in directing treatment strategies in ARDS patients.

Authors:  Benjamin Coiffard; Laurent Papazian
Journal:  Intensive Care Med       Date:  2018-08-23       Impact factor: 17.440

Review 8.  Collateral damage: necroptosis in the development of lung injury.

Authors:  Hilary Faust; Nilam S Mangalmurti
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-11-27       Impact factor: 5.464

9.  Clinical Predictors of Hospital Mortality Differ Between Direct and Indirect ARDS.

Authors:  Liang Luo; Ciara M Shaver; Zhiguo Zhao; Tatsuki Koyama; Carolyn S Calfee; Julie A Bastarache; Lorraine B Ware
Journal:  Chest       Date:  2016-09-20       Impact factor: 9.410

10.  The ABO histo-blood group, endothelial activation, and acute respiratory distress syndrome risk in critical illness.

Authors:  John P Reilly; Nuala J Meyer; Michael Gs Shashaty; Brian J Anderson; Caroline Ittner; Thomas G Dunn; Brian Lim; Caitlin Forker; Michael P Bonk; Ethan Kotloff; Rui Feng; Edward Cantu; Nilam S Mangalmurti; Carolyn S Calfee; Michael A Matthay; Carmen Mikacenic; Keith R Walley; James Russell; David C Christiani; Mark M Wurfel; Paul N Lanken; Muredach P Reilly; Jason D Christie
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.